Eyenovia to present at the Ophthalmology Innovation Summit (OIS) Presbyopia Innovation Showcase
Eyenovia to present at the Ophthalmology Innovation Summit (OIS) Presbyopia Innovation Showcase
NEW YORK–(BUSINESS WIRE)–Jan. 26, 2021– Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that Dr. David Wirta will speak at the Ophthalmology Innovation Summit Presbyopia Innovation Showcase on January 28th.
Dr. Wirta’s presentation will outline the challenges that presbyopia patients face, and the potential benefits of administering pilocarpine through Eyenovia’s novel Optejet® dispenser. The company is currently evaluating its proprietary pilocarpine formulation in the Optejet dispenser (MicroLine1) in two Phase 3 studies, VISION-1 and VISION-2. The VISION program commenced enrollment in December 2020.